Table 1.
Multivariate analysis of the risk of any recurrence (either local or systemic) related to several variables, including the three different surgical approaches.
| Events | Systemic Recurrences | Local Recurrences | OR (95% CI), p-Value) | |
|---|---|---|---|---|
| Groups | ||||
| Study Group (SG) | 4/121 (3.3%) | 3/121 (2.5%) | 1/121 (0.8%) | 0.0456 (0.0075 to 0.2753) p = 0.0008 |
| Control Group 1 (CG1) | 5/50 (10%) | 2/50 (4%) | 3/50 (6%) | 0.1481 (0.0255 to 0.8604) p = 0.0334 |
| Control Group 2 (CG2) | 3/7 (43%) | 2/7 (29%) | 1/7 (15%) | Ref. |
| Age | ||||
| ≤50 | 4/116 (3.5%) | 2/116 (1.8%) | 2/116 (1.8%) | Ref. |
| ≥50 | 8/62 (13%) | 3/62 (4.8%) | 5/62 (8.1%) | 4.1481 (1.1963 to 14.3832) p = 0.0249 |
| Stage | ||||
| 0–I | 4/93 (4.3%) | 1/93 (1.1%) | 3/93 (3.2%) | Ref. |
| II–III | 8/85 (9.4%) | 4/85 (4.7%) | 4/85 (4.7%) | 2.3117 (0.6700 to 7.9756) p = 0.1848 |
| Lympho-vascular invasion | ||||
| No | 5/112 (4.5%) | 2/112 (1.8%) | 2/112 (1.8%) | Ref. |
| Yes | 7/66 (10.7%) | 3/66 (4.5%) | 5/66 (7.6%) | 2.5390 (0.7718 to 8.3530) p = 0.1251 |
| Adjuvant or neoadjuvant chemotherapy | ||||
| No | 4/79 (5.1%) | 3/79 (3.7%) | 5/79 (6.3%) | Ref. |
| Yes | 8/99 (8.1%) | 2/99 (2.0%) | 2/99 (2.0%) | 1.6484 (0.4777 to 5.6879) p = 0.4290 |
| Adjuvant hormone therapy | ||||
| No | 4/61 (6.6%) | 2/61 (3.3%) | 2/61 (3.3%) | Ref. |
| Yes | 8/117 (6.9%) | 3/117 (2.5%) | 5/117 (4.3%) | 1.0459 (0.3020 to 3.6223) p = 0.9436 |
| Adjuvant radiation therapy | ||||
| No | 8/149 (5.4%) | 3/149 (3.0%) | 5/149 (3.3%) | Ref. |
| Yes | 4/29 (14.0%) | 2/29 (7.0%) | 2/29 (7.0%) | 2.8200 (0.7893 to 10.0757) p = 0.1105 |
| Body Mass Index | ||||
| ≤30 | 3/116 (2.6%) | 1/116 (0.8%) | 2/116 (1.8%) | Ref. |
| ≥30 | 9/62 (14.5%) | 4/62 (6.4%) | 5/62 (8.2%) | 6.3962 (1.6635 to 24.5940) p = 0.0069 |
OR = Odds Ratio; CI = Confidence Interval; Ref. = Reference category.